Search

Your search keyword '"Masterson T"' showing total 283 results
Start Over Author "Masterson T"
283 results on '"Masterson T"'

3. Is there a relationship between malocclusion and bullying? A systematic review

Author

Sylvia Karla P. C. Tristão, Marcela B. Magno, Andréa Vaz Braga Pintor, Ilana F. O. Christovam, Daniele Masterson T. P. Ferreira, Lucianne Cople Maia, and Ivete Pomarico Ribeiro de Souza

Subjects
Malocclusion, Bullying, Child, Adolescent, Dentistry, RK1-715
Abstract

Abstract Background Malocclusion is a highly prevalent public health problem, and several studies have shown its negative correlation with quality of life, self-esteem, and social perceptions. However, its association with bullying is still controversial. Objectives To evaluate the relationship between malocclusion and bullying in children and adolescents. Search methods The databases used for the electronic researches were PubMed, Scopus, Lilacs/BBO, Web of Science, and Cochrane Library. Grey literature was reviewed through Open Grey literature with no language or date restrictions. Selection criteria, based on the PECO strategy, were considered eligible observational studies that included schoolchildren or adolescents (P) with malocclusion (E), compared to those with normal occlusion (C), in which the relationship between malocclusion and bullying was determined (O). Data collection and analysis Risk of bias evaluation was made for the qualitative synthesis by the Fowkes and Fulton criteria. Data regarding the age of participants and types of malocclusion and of bullying were extracted among other reported data. The quality of the evidence analyzed was evaluated through the GRADE approach. Results From 2744 articles identified in databases, nine met the eligibility criteria and were included in present systematic review, of which two studies were judged with methodological soundness. The quality of the evidence was classified as very low due to very serious problems for “risk of bias” and “other considerations” and serious problems of “indirectness”. The age of participants ranged from 9 to 34 years considering a cohort study, with a bullying recalling perspective. Malocclusion was both evaluated by researchers and self-reported by participants addressing dentofacial characteristics mostly related to the incisors relationship. All studies evaluated the verbal type of bullying, while 3 also considered physical type. Both types were reported as related to malocclusion, although the results showed that extreme maxillary overjet (> 4 mm, > 6 mm, > 9 mm), extreme deep overbite, and having space between anterior teeth or missing teeth were the types of malocclusion with the strongest relations to bullying. Conclusions With very low certainty of evidence, the results of this systematic review suggest that conspicuous extreme malocclusion may be related to the occurrence of bullying among children and adolescents.

Published
2020
Full Text
View/download PDF

11. P42 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, FROM MONUMENTAL-1

Author

van de Donk, N., primary, Rasche, L., additional, Touzeau, C., additional, Chari, A., additional, Schinke, C., additional, Minnema, M., additional, Berdeja, J., additional, Oriol, A., additional, Rodriguez-Otero, P., additional, Askari, E., additional, Mateos, M., additional, Costa, L., additional, Caers, J., additional, Krishnan, A., additional, Vishwamitra, D., additional, Ma, J., additional, Qin, X., additional, Gries, K.S., additional, Kato, K., additional, Campagna, M., additional, Masterson, T., additional, Hilder, B., additional, Tolbert, J., additional, Renaud, T., additional, Goldberg, J., additional, Heuck, C., additional, Moreau, P., additional, and San-Miguel, J., additional

Published
2023
Full Text
View/download PDF

12. P29 PHASE 1/2 RESULTS OF TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) (MONUMENTAL-1)

Author

Minnema, M.C., primary, Chari, A., additional, Touzeau, C., additional, Schinke, C., additional, Berdeja, J., additional, Oriol, A., additional, van, de Donk N., additional, Otero, P.R., additional, Askari, E., additional, Mateos, M.V., additional, Costa, L.J., additional, Caers, J., additional, Rasche, L., additional, Krishnan, A., additional, Vishwamitra, D., additional, Ma, X., additional, Qin, X., additional, Gries, K.S., additional, Campagna, M., additional, Masterson, T., additional, Hilder, B., additional, Tolbert, J., additional, Renaud, T., additional, Goldberg, J.D., additional, Heuck, C., additional, Miguel, J.S., additional, and Moreau, P., additional

Published
2023
Full Text
View/download PDF

21. Gene Editing/Gene Therapies: MOVING THE NEEDLE FOR CELL THERAPIES: A NEXT-GENERATION EX VIVO PLATFORM USING NANONEEDLES FOR PRECISION CARGO DELIVERY

Author

Syed, N., primary, Narasimha, A., additional, Webb, M., additional, Lesnik, J., additional, Vishwanathan, G., additional, Otto, L., additional, Chooljian, M., additional, Tahmasebipour, A., additional, Aluri, V., additional, Preetam, S., additional, Chow, Y., additional, Nguyen, C., additional, Pietropaoli, L., additional, Higley, S., additional, Masterson, T., additional, Onikoyi, J. Adetunji, additional, Steele, D., additional, Chou, E., additional, Tondar, A., additional, and Goetesh, L., additional

Published
2023
Full Text
View/download PDF

31. Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO)

Author

San-Miguel, J, Usmani, SZ, Mateos, MV, van de Donk, NWCJ, Kaufman, JL, Moreau, P, Oriol, A, Plesner, T, Benboubker, L, Liu, K, Hellemans, P, Masterson, T, Clemens, PL, Luo, M, Farnsworth, A, Nahi, H, and Chari, A

Abstract

Intravenous daratumumab is approved for the treatment of multiple myeloma. In part 1 of the PAVO study, a mix-and-deliver subcutaneous formulation of daratumumab with recombinant human hyaluronidase PH20 (rHuPH20) was well tolerated, with low rates of infusion-related reactions and an efficacy similar to that of intravenous daratumumab. Part 2 of PAVO evaluated a concentrated, pre-mixed co-formulation of daratumumab and rHuPH20 (DARA SC). Patients who had received two or more prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, were given daratumumab (1,800 mg) and rHuPH20 (30,000 U) in 15 mL subcutaneously over 3 to 5 minutes as per the approved intravenous monotherapy dosing schedule. Primary endpoints were daratumumab trough concentration at the end of weekly dosing (just prior to the day 1 dose of cycle 3) and safety. Twenty-five patients were enrolled in PAVO part 2. DARA SC achieved daratumumab trough concentrations similar to or greater than those achieved with intravenous daratumumab 16 mg/kg. The adverse event profile of DARA SC was consistent with that of intravenous daratumumab, with no new safety concerns and a lower infusion-related reaction rate. At a median follow-up of 14.2 months, the overall response rate was 52%, the median duration of response was 15.7 months, and the median progression-free survival was 12.0 months. DARA SC 1,800 mg was well tolerated in relapsed/refractory multiple myeloma, with a low infusion-related reaction rate and reduced administration time. Daratumumab serum concentrations following DARA SC were consistent with those following intravenous dosing, and deep and durable responses were observed. Based on these results, ongoing studies are investigating DARA SC in the treatment of multiple myeloma and other conditions.

Published
2021

50. S823 RANDOMIZED, OPEN-LABEL, NON-INFERIORITY, PHASE 3 STUDY OF SUBCUTANEOUS (SC) VERSUS INTRAVENOUS (IV) DARATUMUMAB (DARA) ADMINISTRATION IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: COLUMBA

Author

Mateos, M.-V., primary, Nahi, H., additional, Legiec, W., additional, Grosicki, S., additional, Vorobyev, V., additional, Spicka, I., additional, Hungria, V., additional, Korenkova, S., additional, Bahlis, N., additional, Flogegard, M., additional, Blade, J., additional, Moreau, P., additional, Kaiser, M., additional, Iida, S., additional, Laubach, J., additional, Ahmadi, T., additional, Clemens, P.L., additional, Masterson, T., additional, Lantz, K., additional, O’Rourke, L., additional, Heuck, C., additional, Peng, L., additional, Parasrampuria, D.A., additional, Yuan, Z., additional, Qi, M., additional, and Usmani, S.Z., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results